Paclitaxel, carboplatin, and cetuximab induction chemotherapy for locally advanced head and neck squamous cell carcinoma: A retrospective evaluation of treatment outcomes and safety. (PubMed, Curr Ther Res Clin Exp) - Sep 24, 2026 - "PCE achieved an 82.7% response rate, CRT completion in 51 of 52 patients (98.1%), and significantly higher cisplatin ≥200 mg/m² achievement (86.5% vs. 59.2%, p = 0.002). PFS was longer in the PCE group after limited adjustment, whereas OS did not differ significantly. Given the retrospective, nonrandomized design, residual confounding, and shorter follow-up in the PCE group, these findings are hypothesis-generating and require confirmation in larger, prospective studies."
Journal • Retrospective data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck
|
|
Ai Yamamoto; Akihiro Sakai; Aritomo Yamazaki; Daisuke Maki; Hiroaki Iijima; Hiroka Tanimizu; Hiroshi Ashida; Kazufumi Obata; Kenji Okami; Koichiro Wasano; Koji Ebisumoto; Mayu Yamauchi; Naoya Kobayashi; Takane Watanabe; Takanobu Teramura; Toshihide Inagi; Toshihisa Kuroki; Tsuyoshi Fukuzawa; Yoshiyuki Ota; Yurina Sato
|